



**Drug Name:** Nucala (mepolizumab)  
**Revised Date:** 12/2018

<b>Drug Name:</b>	<b>Nucala (mepolizumab)</b>
<b>Exclusion Criteria:</b>	n/a
<b>Required Medical Information:</b>	<p><b>Eosinophilic Asthma</b>            Authorization of 12 months may be granted for treatment of eosinophilic asthma when all of the following criteria are met:</p> <ul style="list-style-type: none"> <li>• Member is 12 years of age or older.</li> <li>• Member has a baseline blood eosinophil count of at least 150 cells per microliter.</li> <li>• Member has a history of severe asthma despite current treatment with both of the following medications at optimized doses:               <ul style="list-style-type: none"> <li>○ Inhaled corticosteroid</li> <li>○ Additional controller (long acting beta<sub>2</sub>-agonist, leukotriene modifier, or sustained-release theophylline)</li> </ul> </li> </ul> <p><b>Eosinophilic Granulomatosis with Polyangiitis</b>            Authorization of 12 months may be granted for treatment of eosinophilic granulomatosis with polyangiitis when all of the following criteria are met:</p> <ul style="list-style-type: none"> <li>• Member is 18 years of age or older.</li> <li>• Member has a history or the presence of an eosinophil count of more than 1000 cells per microliter or a blood eosinophil level of greater than 10%.</li> </ul>
<b>Renewal Criteria</b>	<p><b>Eosinophilic asthma</b>            Authorization of 12 months may be granted for continuation of treatment of eosinophilic asthma when all of the following criteria are met:</p> <ul style="list-style-type: none"> <li>• Member is 12 years of age or older.</li> <li>• Asthma control has improved on Nucala treatment as demonstrated by either:               <ul style="list-style-type: none"> <li>○ A reduction in the frequency or severity of symptoms and exacerbations, OR a reduction in the daily maintenance oral corticosteroid dose</li> </ul> </li> </ul> <p><b>Eosinophilic Granulomatosis with Polyangiitis</b>            Authorization of 12 months may be granted for continuation of treatment of eosinophilic granulomatosis with polyangiitis when all of the following criteria are met:</p> <ul style="list-style-type: none"> <li>• Member is 18 years of age or older.</li> <li>• Member has beneficial response to treatment with Nucala as</li> </ul>

demonstrated by any of the following:

- A reduction in the frequency of relapses, or
- A reduction in the daily oral corticosteroid dose, or
- No active vasculitis